ALOX12B promotes carcinogenesis in cervical cancer by regulating the PI3K/ERK1 signaling pathway

Jiang,Tao; Zhou,Bing; Li,Yuan   Meng; Yang,Qui   Ying; Tu,Kai   Jia; Li,Long   Yu

doi:10.3892/ol.2020.11641

ALOX12B promotes carcinogenesis in cervical cancer by regulating the PI3K/ERK1 signaling pathway

Authors:
- Tao Jiang
- Bing Zhou
- Yuan Meng Li
- Qui Ying Yang
- Kai Jia Tu
- Long Yu Li
View Affiliations

Affiliations: Department of Gynecological Oncology, Jiangxi Medical College of Nanchang University, Nanchang, Jiangxi 330031, P.R. China, Department of Pathology, The Affiliated Jiujiang Hospital of Nanchang University, Jiujiang, Jiangxi 332000, P.R. China, Department of Gynecology, The Affiliated Jiujiang Hospital of Nanchang University, Jiujiang, Jiangxi 332000, P.R. China, Department of Gynecological Oncology, Jiangxi Maternal and Child Health Hospital, Nanchang, Jiangxi 330006, P.R. China
Published online on: May 19, 2020 https://doi.org/10.3892/ol.2020.11641
Pages: 1360-1368
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cervical cancer is a malignant disease and a threat to women's health worldwide. Surgical resection followed by radiotherapy or chemotherapy is the main treatment strategy for cervical cancer; however, patients with cervical cancer, especially those with late‑stage disease, may not benefit from these traditional therapies, which results in poor clinical outcome. ALOX12B is a gene encoding lipoxygenase, and a mutation in ALOX12B was detected in lung and breast cancer. Furthermore, ALOX12B is essential to the proliferation of epidermoid carcinoma cells; however, the role of ALOX12B in cervical cancer has not been studied thus far, to the best of our knowledge. In the present study, the expression levels of ALOX12B were reduced in cervical cancer cells by lentiviral transfection, and it was found that both cell proliferation and clone formation ability were significantly reduced, and the cell cycle was blocked at G1 phase. Tumor growth was also suppressed in vivo in a xenograft tumor model, but the migration of tumor cells was not affected by ALOX12B. Subsequently, using western blotting, it was demonstrated that knockdown of ALOX12B decreased the expression levels of PI3K, MEK1, ERK1, C‑fos and cdc25. Meanwhile, overexpression of ALOX12B increased the expression levels of these five molecules. Conclusively, ALOX12B promoted cell proliferation in cervical cancer via regulation of the PI3K/ERK1 signaling pathway. The present study may improve our understanding of the molecular mechanisms underlying the function of ALOX12B in cervical cancer and inform new therapeutic strategies.

View Figures

View References

1	Johnson CA, James D, Marzan A and Armaos M: Cervical Cancer: An Overview of Pathophysiology and Management. Semin Oncol Nurs. 35:166–174. 2019. View Article : Google Scholar : PubMed/NCBI
2	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
3	Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
4	Liontos M, Kyriazoglou A, Dimitriadis I, Dimopoulos MA and Bamias A: Systemic therapy in cervical cancer: 30 years in review. Crit Rev Oncol Hematol. 137:9–17. 2019. View Article : Google Scholar : PubMed/NCBI
5	Leahy AB, Elgarten CW, Grupp SA, Maude SL and Teachey DT: Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia. Expert Rev Anticancer Ther. 18:959–971. 2018. View Article : Google Scholar : PubMed/NCBI
6	Kwok G, Yau TC, Chiu JW, Tse E and Kwong YL: Pembrolizumab (Keytruda). Hum Vaccin Immunother. 12:2777–2789. 2016. View Article : Google Scholar : PubMed/NCBI
7	Fang J, Zhang H and Jin S: Epigenetics and cervical cancer: From pathogenesis to therapy. Tumour Biol. 35:5083–5093. 2014. View Article : Google Scholar : PubMed/NCBI
8	Krieg P, Marks F and Fürstenberger G: A gene cluster encoding human epidermis-type lipoxygenases at chromosome 17p13.1: Cloning, physical mapping, and expression. Genomics. 73:323–330. 2001. View Article : Google Scholar : PubMed/NCBI
9	Mashima R and Okuyama T: The role of lipoxygenases in pathophysiology; new insights and future perspectives. Redox Biol. 6:297–310. 2015. View Article : Google Scholar : PubMed/NCBI
10	Kurban M, Shimomura Y, Bahhady R, Ghosn S, Kibbi AG and Christiano AM: Nonsense mutation in the ALOX12B gene leads to autosomal recessive congenital ichthyosis in a Lebanese family. J Eur Acad Dermatol Venereol. 24:232–234. 2010. View Article : Google Scholar : PubMed/NCBI
11	Rodríguez-Pazos L, Ginarte M, Vega A and Toribio J: Autosomal recessive congenital ichthyosis. Actas Dermosifiliogr. 104:270–284. 2013. View Article : Google Scholar : PubMed/NCBI
12	Rooney MS, Shukla SA, Wu CJ, Getz G and Hacohen N: Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 160:48–61. 2015. View Article : Google Scholar : PubMed/NCBI
13	Shen M, Vermeulen R, Rajaraman P, Menashe I, He X, Chapman RS, Yeager M, Thomas G, Burdett L, Hutchinson A, et al: Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China. Environ Mol Mutagen. 50:285–290. 2009. View Article : Google Scholar : PubMed/NCBI
14	Lee JY, Park AK, Lee KM, Park SK, Han S, Han W, Noh DY, Yoo KY, Kim H, Chanock SJ, et al: Candidate gene approach evaluates association between innate immunity genes and breast cancer risk in Korean women. Carcinogenesis. 30:1528–1531. 2009. View Article : Google Scholar : PubMed/NCBI
15	Agarwal S, Achari C, Praveen D, Roy KR, Reddy GV and Reddanna P: Inhibition of 12-LOX and COX-2 reduces the proliferation of human epidermoid carcinoma cells (A431) by modulating the ERK and PI3K-Akt signalling pathways. Exp Dermatol. 18:939–946. 2009. View Article : Google Scholar : PubMed/NCBI
16	Bernard B, Fest T, Prétet JL and Mougin C: Staurosporine-induced apoptosis of HPV positive and negative human cervical cancer cells from different points in the cell cycle. Cell Death Differ. 8:234–244. 2001. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Δ Δ C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
19	Khajah MA, Mathew PM and Luqmani YA: Inhibitors of PI3K/ERK1/2/p38 MAPK Show Preferential Activity Against Endocrine-Resistant Breast Cancer Cells. Oncol Res. 25:1283–1295. 2017. View Article : Google Scholar : PubMed/NCBI
20	Taciak B, Pruszynska I, Kiraga L, Bialasek M and Krol M: Wnt signaling pathway in development and cancer. J Physiol Pharmacol. 69:692018.
21	Zeng H: mTOR signaling in immune cells and its implications for cancer immunotherapy. Cancer Lett. 408:182–189. 2017. View Article : Google Scholar : PubMed/NCBI
22	Tsikouras P, Zervoudis S, Manav B, Tomara E, Iatrakis G, Romanidis C, Bothou A and Galazios G: Cervical cancer: Screening, diagnosis and staging. J BUON. 21:320–325. 2016.PubMed/NCBI
23	Le Gallo M, Lozy F and Bell DW: Next-Generation Sequencing. Adv Exp Med Biol. 943:119–148. 2017. View Article : Google Scholar : PubMed/NCBI
24	Chang S, Sun L and Feng G: SP1-mediated long noncoding RNA POU3F3 accelerates the cervical cancer through miR-127-5p/FOXD1. Biomed Pharmacother. 117:1091332019. View Article : Google Scholar : PubMed/NCBI
25	Fasterius E, Uhlén M and Al-Khalili Szigyarto C: Single-cell RNA-seq variant analysis for exploration of genetic heterogeneity in cancer. Sci Rep. 9:95242019. View Article : Google Scholar : PubMed/NCBI
26	Crook T, Wrede D, Tidy JA, Mason WP, Evans DJ and Vousden KH: Clonal p53 mutation in primary cervical cancer: Association with human-papillomavirus-negative tumours. Lancet. 339:1070–1073. 1992. View Article : Google Scholar : PubMed/NCBI
27	Thomas M, Pim D and Banks L: The role of the E6-p53 interaction in the molecular pathogenesis of HPV. Oncogene. 18:7690–7700. 1999. View Article : Google Scholar : PubMed/NCBI
28	Justus CR, Leffler N, Ruiz-Echevarria M and Yang LV: In vitro cell migration and invasion assays. J Vis Exp. 88:510462014.
29	Tian R, Zuo X, Jaoude J, Mao F, Colby J and Shureiqi I: ALOX15 as a suppressor of inflammation and cancer: Lost in the link. Prostaglandins Other Lipid Mediat. 132:77–83. 2017. View Article : Google Scholar : PubMed/NCBI
30	Ding XZ, Tong WG and Adrian TE: Cyclooxygenases and lipoxygenases as potential targets for treatment of pancreatic cancer. Pancreatology. 1:291–299. 2001. View Article : Google Scholar : PubMed/NCBI
31	Bossler F, Hoppe-Seyler K and Hoppe-Seyler F: PI3K/AKT/mTOR Signaling Regulates the Virus/Host Cell Crosstalk in HPV-Positive Cervical Cancer Cells. Int J Mol Sci. 20:202019. View Article : Google Scholar
32	De Luca A, Maiello MR, D'Alessio A, Pergameno M and Normanno N: The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: Role in cancer pathogenesis and implications for therapeutic approaches. Expert Opin Ther Targets. 16 (Suppl 2):S17–S27. 2012. View Article : Google Scholar : PubMed/NCBI
33	Milde-Langosch K: The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer. 41:2449–2461. 2005. View Article : Google Scholar : PubMed/NCBI
34	Brenner AK, Reikvam H, Lavecchia A and Bruserud Ø: Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia - the possibility to target several kinases through inhibition of the various CDC25 isoforms. Molecules. 19:18414–18447. 2014. View Article : Google Scholar : PubMed/NCBI